Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and thirteen have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $710.93.
MDGL has been the subject of several analyst reports. The Goldman Sachs Group initiated coverage on shares of Madrigal Pharmaceuticals in a research note on Thursday, September 24th. They issued a “buy” rating and a $704.00 price objective for the company. HC Wainwright reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, October 15th. Canaccord Genuity Group raised their price target on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Finally, Barclays dropped their price objective on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a report on Monday, August 3rd.
Check Out Our Latest Stock Analysis on Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Trading Down 4.6%
Shares of MDGL opened at $378.64 on Friday. The company’s fifty day simple moving average is $462.32 and its 200-day simple moving average is $493.62. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.05 and a quick ratio of 2.78. Madrigal Pharmaceuticals has a twelve month low of $353.54 and a twelve month high of $615.00.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $2.92. The firm had revenue of $431.27 million during the quarter, compared to analysts’ expectations of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. During the same period in the previous year, the company earned ($5.08) EPS. On average, equities research analysts expect that Madrigal Pharmaceuticals will post -2.08 earnings per share for the current year.
Insiders Place Their Bets
In other news, CEO William Sibold sold 5,221 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $542.39, for a total transaction of $2,831,818.19. Following the completion of the sale, the chief executive officer directly owned 197,746 shares of the company’s stock, valued at approximately $107,255,452.94. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bros. Advisors Lp Baker purchased 76,140 shares of the business’s stock in a transaction dated Friday, November 6th. The stock was bought at an average price of $384.32 per share, for a total transaction of $29,262,124.80. Following the completion of the acquisition, the director owned 2,040,682 shares of the company’s stock, valued at approximately $784,274,906.24. The trade was a 3.88% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 12,660 shares of company stock worth $6,670,042 over the last quarter. Company insiders own 17.60% of the company’s stock.
Institutional Investors Weigh In On Madrigal Pharmaceuticals
Large investors have recently added to or reduced their stakes in the stock. Persistent Asset Partners Ltd purchased a new stake in shares of Madrigal Pharmaceuticals in the second quarter valued at approximately $29,000. Global Retirement Partners LLC purchased a new position in Madrigal Pharmaceuticals during the 2nd quarter worth $34,000. Jacobi Capital Management LLC purchased a new position in Madrigal Pharmaceuticals during the 3rd quarter worth $54,000. Provenance Wealth Advisors LLC bought a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at $69,000. Finally, Root Financial Partners LLC bought a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at $82,000. 98.50% of the stock is owned by hedge funds and other institutional investors.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania. Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.
Further Reading
- Five stocks we like better than Madrigal Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
